You are browsing the archive for Johnson & Johnson Development Corporation - peHUB.

Avatar of Staff

by Staff

Celladon Wraps Up $43M Round

Posted on: February 15, 2012 by StaffNo Comments »

Celladon Corp., a developer of treatments for cardiovascular diseases, has closed on $43 million in new capital. Pfizer Venture Investments led the round, which included investment from new backers Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners. All previous investors participated in this round, including Enterprise Partners Venture Capital, Johnson [...]

PowerVision Completes Funding Round

Posted on: January 24, 2012 by asormaniNo Comments »

PowerVision, a private company developing an accommodating intraocular lens, had added Johnson & Johnson Development Corporation to its list of investors in a recent closing of its Series C financing. Current investors, Venrock, Advanced Technology Ventures, and Frazier Healthcare Ventures, also participated in the round. The closing brings PowerVision’s Series C financing round to a [...]

Avatar of cnolan

by cnolan

Catalyst Biosciences Inks $7M from Phizer

Posted on: January 6, 2012 by cnolanNo Comments »

Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.

Avatar of cnolan

by cnolan

Nevro Inks $58M For Chronic Pain Treatment

Posted on: July 20, 2011 by cnolanNo Comments »

Menlo Park, Calif.-based Nevro Corp., a neuromodulation company focused on relief of chronic pain, has sealed a whopping $58 million round led by new investor Johnson & Johnson Development Corporation. Existing shareholders Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners also participated. The money will go toward a clinical study in the US and to support the company’s commercialization strategy.

Avatar of cnolan

by cnolan

VC-backed Genocea Names Chip Clark CEO

Posted on: February 2, 2011 by cnolan1 Comment »

Cambridge, Mass.-based vaccine development company Genocea Biosciences has named Chip Clark president and chief executive officer. Clark joined the company last August as chief business officer. Genocea is backed by investors including Johnson & Johnson Development Corporation, Skyline Ventures, MP Healthcare Venture Management and Polaris Venture Partners.